explore -WSS

explore

author：leisure time 2025-08-04 03:43:31 - browse：81266

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Roche to buy Carmot Therapeutics, developer of obesity drugs

hotspot

WSS

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Device maker Teleflex to acquire urology company for $600M

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

How doctors’ personal politics affect patients

How doctors’ personal politics affect patients

Pharma patents targeted by Biden in move to slash drug prices

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Jerome Adams on the need for new antivirals for Covid

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Jerome Adams on the need for new antivirals for Covid

Leukemia patients are helped by Syndax's new type of therapy

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Pregnancy discrimination could be enabled by AI

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

CDC Director Mandy Cohen on transparency, trust, and health

BioMarin wins approval for gene therapy to treat hemophilia A

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

focus

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

CDC Director Mandy Cohen on transparency, trust, and health

Leukemia patients are helped by Syndax's new type of therapy

How doctors’ personal politics affect patients

Leukemia patients are helped by Syndax's new type of therapy

A new crop of companies is reshaping the health data economy

hotspot

leisure time

hotspot

focus